formalises collaboration with manufacturers

Sydney - Wednesday - Sep 5: (RWE Australian Business News) -
QRSciences Holdings Ltd (ASX code: QRS), a leader in the development of
Quadrupole Resonance (QR) technology, has entered an agreement with
AstraZeneca (AZ), Merck, Sharp and Dohme (MSD) and King's College London
(KCL) to develop a QR-based pharmaceutical analysis instrument.
The partnership brings together end-users and technology
suppliers to develop a QR-based system for various roles within the
pharmaceutical drug discovery and manufacturing industry.
QR technology, a radio frequency (RF) spectroscopic method, can
be used in the quantification of pharmaceuticals and the identification
of polymorphs, as well as detection, analysis and quality control of
pharmaceuticals at all stages of the manufacturing and distribution
chain.
The two main objectives of the collaborative project are to
develop a prototype pulsed RF QR spectrometer suitable for use in
pharmaceutical analysis and to extend the range of substances that can
be detected by focusing on higher frequencies.
The project will be conducted at QRSciences's facilities in
Western Australia, at King's College London and at MSD's and AZ's
respective research facilities at Hoddesdon and Macclesfield in the UK.